Cancer Institute of New Jersey (CINJ), Hematologic Malignancies

Filter
Letter

Search results

  • 2022

    Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study

    Epperla, N., Zhao, Q., Chowdhury, S. M., Shea, L., Moyo, T. K., Reddy, N., Sheets, J., Weiner, D. M., Geethakumari, P. R., Kandarpa, M., Bruno, X. J., Thomas, C., Churnetski, M. C., Hsu, A., Zurbriggen, L., Tan, C., Lindsey, K., Maakaron, J., Caimi, P. F., Torka, P., & 25 othersBello, C., Ayyappan, S., Karmali, R., Kim, S. H., Kress, A., Kothari, S., Sawalha, Y., Christian, B., David, K. A., Greenwell, I. B., Janakiram, M., Kenkre, V. P., Olszewski, A. J., Cohen, J. B., Palmisiano, N., Umyarova, E., Wilcox, R. A., Awan, F. T., Alderuccio, J. P., Barta, S. K., Grover, N. S., Ghosh, N., Bartlett, N. L., Herrera, A. F. & Shouse, G., Dec 2022, In: Journal of Hematology and Oncology. 15, 1, 96.

    Research output: Contribution to journal › Letter › peer-review

    Open Access